In this episode Dr Wilson Lim interviews our guest Prof. Carlos Fernández de Larrea on CAR-T toxicities and how to control or avoid adverse reactions to CAR-T therapies in patients with myeloma. Guest: Prof. Carlos Fernández de Larrea ; Host: Dr Wilson Lim This podcast episode is part of our FREE course on CAR-T Updates on the EHA Campus . Prominent experts provide an overview of CAR-T treatment in different diseases, discussing clinical management, economic and regulator...
Jul 07, 2023•7 min•Ep 74•Transcript available on Metacast Listen as Dr. Anna Sureda discusses CAR-T therapy from a patients perspective and the steps that physicians can take to help patients overcome the challenges that comes with CAR-T treatment. This podcast episode is part of our FREE course on CAR-T Updates on the EHA Campus . Prominent experts provide an overview of CAR-T treatment in different diseases, discussing clinical management, economic and regulatory aspects, and future developments. What did you thi...
Jun 30, 2023•6 min•Ep 73•Transcript available on Metacast Listen as Emeritus Prof Robin Foà brings you on the journey of Ph+ ALL management together with our host Dr Enrica Orsini. With a long career in ALL, Prof Foà runs through the history of Ph+ ALL, his experience in patient management, and then brings you up to date on the current picture in patient management. Tune in as Prof Foà describes the breakthrough in treatment with TKI inhibitors and the introduction of the immunotherapeutic drug blinatumomab in Ph+ ALL. Guest: Emeritus Prof. Robin Foà H...
Jun 23, 2023•24 min•Ep 72•Transcript available on Metacast Join us for another episode of EHA Unplugged. We have Prof. Herman Einsele here talking about the current landscapes of CAR-T therapy in myeloma, results achievable today, and the future perspectives for these patients. This podcast episode is part of our FREE course on CAR-T Updates on the EHA Campus . Prominent experts provide an overview of CAR-T treatment in different diseases, discussing clinical management, economic and regulatory aspects, and future developments. &...
Jun 02, 2023•7 min•Ep 71•Transcript available on Metacast Join us here at EHA Unplugged with another episode on CAR-T updates. Listen as our guest Prof. Chiara Bonini and host Dr. Wilson Lim discuss the reasons for CAR-T therapy failure and relapse after treatment. This podcast episode is part of our FREE course on CAR-T Updates on the EHA Campus . Prominent experts provide an overview of CAR-T treatment in different diseases, discussing clinical management, economic and regulatory aspects, and future developments. &n...
May 26, 2023•14 min•Ep 70•Transcript available on Metacast Listen as Prof. Christian Chabannon provides an overview of the challenges and obstacles raised by the economic aspects of CAR-T treatment. He examines different solutions and proposes a way forward to address these issues. This podcast episode is part of our FREE course on CAR-T Updates on the EHA Campus . Prominent experts provide an overview of CAR-T treatment in different diseases, discussing clinical management, economic and regulatory aspects, and futur...
May 18, 2023•19 min•Ep 69•Transcript available on Metacast Listen as Prof. John Gribben provides an update on where we are with CAR-T in acute and chronic leukemias. This podcast episode is part of our FREE course on CAR-T Updates on the EHA Campus . Prominent experts provide an overview of CAR-T treatment in different diseases, discussing clinical management, economic and regulatory aspects, and future developments. What did you think of this podcast? Share your opinions with us in a short feedback survey. Lear...
May 12, 2023•8 min•Ep 68•Transcript available on Metacast Prof Günter Weiss, from the University of Innsbruck, Germany, provides in this podcast a comprehensive pathogenetic and clinical overview of a relevant and frequent medical problem: Absolute Iron Deficiency, defined as the combination of anemia of chronic disease (ACD) and iron deficiency anemia (IDA) in people suffering from inflammatory disorders. The complex functional mechanisms and underlying diseases at work in these patients make the diagnostic work-up and treatment choices difficult and ...
Apr 28, 2023•19 min•Ep 67•Transcript available on Metacast Listen as Prof. Carl June provides an overview of the past and current landscape and challenges in CAR-T therapy, along with a summary of the innovations being introduced to lower the cost of CAR-T and improve CAR-T treatment and access. This podcast episode is part of our FREE course on CAR-T Updates on the EHA Campus . Prominent experts provide an overview of CAR-T treatment in different diseases, discussing clinical management, economic and regulatory aspects, and future developments. W...
Apr 21, 2023•10 min•Ep 66•Transcript available on Metacast In this podcast, Hartmut Döhner, Hematologist-Oncologist and Professor of Medicine in Germany, discusses with Dr. Nathalie van Havre the role of genomic characterization in the classification, prognosis and treatment of myeloid neoplasms. Discover the main methods of genomic testing, the kind of relevant information they can provide, and the essential techniques that should currently be available for hematology centers. The podcast also explores the significance of germline variants and the need...
Apr 14, 2023•15 min•Ep 65•Transcript available on Metacast In this podcast about gene therapy for hemoglobinopathies, our experts Dr. Evangelia Yanaki and Professor Franco Locatelli discuss the most effective approach for treating patients with these conditions, considering the safety concerns and potential complications associated, as well as the need for long-term monitoring of patients. In this debate recorded during the EHA22 Annual Congress, Dr. Yanaki advocates for gene addition therapy, while Professor Locatelli favors genome editing as a m...
Apr 07, 2023•41 min•Ep 64•Transcript available on Metacast In this episode, guest Prof Martin Dreyling and host Dr Nathalie van Havre discuss the latest developments in lymphoid malignancies and the research roadmap that has been put in place to guide future research. Professor Dreyling highlights the move away from traditional chemotherapy towards non-cytostatic approaches and discusses the long-term complications of traditional treatments and the need for precision therapy. Host: Dr Nathalie van Havre; Guest: Prof Martin Dreyling Learn More What did y...
Mar 31, 2023•18 min•Ep 63•Transcript available on Metacast In this episode of EHA Unplugged, Prof Beverly Hunt discusses the global consequences of postpartum hemorrhage (PPH) and the unacceptable PPH-related mortality rate in developed countries. The discussion continues on the challenges faced in the identification of PPH and the primary causes of PPH. Prof Hunt further talks about the consequences of PPH on children and emphasizes the need for more research in PPH and campaigns to improve maternal health. Guest: Prof Beverly Hunt This pod...
Mar 24, 2023•23 min•Ep 62•Transcript available on Metacast Join Prof Paolo Ghia and our host Dr Enrica Orsini as they discuss the treatment of Chronic Lymphocytic Leukemia (CLL) from the perspectives of patients and doctors. In this episode, they discuss the factors that influence the decision of treatment choices from the perspectives of patients and doctors and how both parties have different perspectives on the subject. They further highlight the importance of understanding the differing priorities between these two groups and the need...
Mar 17, 2023•9 min•Ep 61•Transcript available on Metacast In this podcast, hear from Prof Hartmut Döhner, Hematologist-Oncologist and Professor of Medicine in Germany, as he discusses the growing roles of precise treatments based on the characteristics of the leukemic cells in acute myeloid leukemias. Discover the clinical developments of targeted treatments such as IDH1/2 inhibitors and venetoclax, and learn about the importance of combination treatment to improve results. The podcast also explores the use of epigenetic agents as part of standard care...
Mar 10, 2023•11 min•Ep 60•Transcript available on Metacast Treatment of low-risk patients with polycythemia vera (PV) and myelofibrosis (MF) is still a matter of debate. Although traditionally these patients were managed exclusively with supportive treatment, more recent guidelines suggest the opportunity of identifying subgroups of patients eligible for cytoreduction. In this debate recorded during the EHA22 Annual Congress, experts Claire Harrison and Christen Lykkegaard Andersen support opposite statements on this topic, discussing the pros and cons ...
Mar 03, 2023•39 min•Ep 59•Transcript available on Metacast Join our guest Dr Martin Kaiser and host Dr Nathalie van Havre, as they talk about Heath Technology Assessment (HTA) in hematology and in Europe’s public healthcare landscape. Our speakers discuss the relevance of HTA for hematologists and how it aims to standardize access to new health technologies for patients across Europe. Furthermore, they examine the challenges in generating solid evidence to support these assessments, particularly in the case of rare diseases, and whether HTAs are likely ...
Mar 01, 2023•20 min•Ep 58•Transcript available on Metacast In this podcast, you will listen to Prof Antonis Kattamis summarizing the last developments in the treatment of patients with thalassemia. While the life expectancy of these patients has considerably improved in the last decades, quality of life and disease burden is still a relevant issue. However, new classes of drugs, with action of the pathophysiologic mechanisms of the disease, are entering the clinics—drugs able to improve globin chain imbalance or ineffective erythropoiesis, or decrease h...
Feb 17, 2023•16 min•Ep 57•Transcript available on Metacast In this podcast, Prof Paolo Ghia discusses the current treatment landscape of Chronic Lymphocytic Leukemia (CLL), providing a guide for clinicians faced with an ever-growing number of therapeutic alternatives. Within targeted therapies, a special focus is dedicated to BTK inhibitors and their different characteristics, and to the long-term results of the ASCEND trial. The management of CLL is changing rapidly, and Prof Ghia's expertise can help hematologists to choose the right treatment for the...
Feb 10, 2023•12 min•Ep 56•Transcript available on Metacast In this podcast, Prof Mario Cazzola illustrates the genesis of the new ICC classification of myeloid neoplasms, published in 2022 (Arber DA et al, Blood 2022), with a special focus on MDS, and the new nosological entities that have been defined in it. The new entities, namely SF3B1 -mutant MDS, TP53 multi-hit MDS, and clonal cytopenia of undetermined significance (CCUS), underline the importance of gene sequencing for the diagnosis and risk stratification of myeloid neoplasms a...
Feb 03, 2023•13 min•Ep 55•Transcript available on Metacast What are the latest guidelines for the management of patients with Transfusion-Dependent Thalassemia (TDT)? In 2022, the fourth edition of the TIF (Thalassemia International Federation) guidelines for the management of patients with transfusion-dependent thalassemia (TDT) was published. In this podcast, Prof Ali Taher discusses with our host, Dr Nathalie van Havre, the main news of this edition, including genetic work-up, chelation therapy, and prevention and management of complications. Further...
Jan 27, 2023•17 min•Ep 54•Transcript available on Metacast Spotlight Talks: Updates on the Classification of Hematolymphoid Neoplasms: Lymphoid Diseases In this podcast, Prof John Gribben, former President of EHA, discusses the new ICC lymphoid malignancies classification (Campo E, et al. Blood, 2022), highlighting the main novelties introduced for specific entities and explaining the new criteria guiding the diagnosis and prognosis of lymphoproliferative diseases. Listen to this podcast to gain an overview of the most innovative findings in the field, ...
Jan 20, 2023•13 min•Ep 53•Transcript available on Metacast Is CAR-T economically sustainable? Join our guest Prof Martin Dreyling and host Dr Nathalie van Havre as they discuss the costs of CAR-T cell therapy for the treatment of blood disorders at an individual level and whether it is economically sustainable for health systems. Listen along as they consider the financial challenges of patient selection for this costly life-saving therapy, based on Prof Dreyling’s experience with relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL) patients. Ch...
Jan 13, 2023•17 min•Ep 52•Transcript available on Metacast What is Plan S and what has happened to it? Join our guest Dr Nuno Borges and host Dr Christian Scharenberg as they talk about the core principles, goals, and challenges of Plan S. Listen along as Dr Borges discusses the controversies aroused by Plan S and the “publish or perish” paradigm faced by early career scientists. Dr Borges ends this podcast on a positive note where he believes that slowly, but surely, and thanks to social media, we are heading towards a future where scientific publicati...
Dec 09, 2022•8 min•Ep 51•Transcript available on Metacast What is clonal hematopoiesis of indeterminate potential (CHIP) and its associated risks in elderly patients? Join our guest Prof Kirsten Gronbaek and host Dr Christian Scharenberg as they discuss CHIP, its biological significance, frequency in the general population, and its association with epigenetic age. Listen along as Prof Gronbaek dives deeper into the subject and explains the association and significance of CHIP with mutations and patient survival. Last but not least, Prof Gronbaek talks ...
Nov 25, 2022•8 min•Ep 50•Transcript available on Metacast What can a not-for-profit NGO do for patients in a time of war? Join our guests, Prof Konstanze Döhner, Prof Elizabeth Macintyre, and Dr Nathalie van Havre as they discuss what the European Hematology Association (EHA) has done in favor of Ukraine and the Ukrainian hematological community. Our guests talk about support programs EHA has implemented and the obstacles that came with that. Prof Macintyre furthers the discussion by expressing her views on the role of medical organizations such as EHA...
Nov 11, 2022•13 min•Ep 49•Transcript available on Metacast Join our guest Prof David Rees and host Dr Christian Scharenberg as they discuss how the concept of precision medicine can be applied to Sickle Cell Disease (SCD). Listen as Prof David Rees talks about prognostic markers and how they can (or can't) guide SCD disease management, current and new treatment options for SCD patients, and how the situation of precision medicine can differ between low- and high-income countries. Last but not least, Prof David Rees ends the podcast with his view of how ...
Oct 28, 2022•11 min•Ep 48•Transcript available on Metacast How did CLL lose its role of "Cinderella" in hematology in the last decades, thanks to the introduction of entirely new classes of drugs, and came under the spotlight of clinical research in hematology? Prof Jennifer Woyach discusses the fundamentals of CLL genetics and treatment in this podcast, as well as the selection of patients for therapy, the different, and somewhat unpredictable, clinical course the disease can follow, together with the last evidence from CLL clinical trials. Host: Prof ...
Jun 10, 2022•13 min•Ep 47•Transcript available on Metacast The links between thrombosis and cancer have been known for a long time and are associated with the type of cancer (pancreatic and lung carcinomas, for example, are particularly prone to give this complication), its localization, and the anti-neoplastic treatment used to fight the cancer itself. Prof Jan Marie Connors, in this podcast, explains how a thrombotic episode may represent the first indication of a cancer diagnosis, and how guidelines should be critically used to manage these patients,...
Jun 03, 2022•17 min•Ep 46•Transcript available on Metacast In this podcast, Prof Tessa Andermann, an expert in infectious diseases, provides an overview of the role of the microbiome in the homeostasis of the human body and how it has been implicated in the development of complications after allogeneic transplantations, including acute graft-versus-host-disease, infections, mortality, and disease relapse. Some of the relationships observed between changes in the microbiome and clinical outcome might in the next future be better characterized and exploit...
May 27, 2022•13 min•Ep 45•Transcript available on Metacast 
